Influence of glycaemic control on platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in Type 2 diabetes

Diabetic Medicine

Volumn 27, Issue 4, 2010, Pages 384-390

  Neubauer, H ^a   Setiadi, P ^a   Gunesdogan B ^b   Pinto, A ^a   Borgel J ^a   Mugge A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Clinic of Cardiology and Angiology Klinikum Lüdenscheid   (Germany)

Author keywords

CD40 CD40L; Diabetes mellitus; Flow cytometry; P selectin; Platelets

Indexed keywords

C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PADGEM PROTEIN; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN;

AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE; THROMBOGENESIS; UPREGULATION; ADULT; BLOOD; FLOW CYTOMETRY; METABOLISM; MIDDLE AGED; THROMBOCYTE;

ADULT; AGED; ANTIGENS, CD40; BLOOD PLATELETS; CD40 LIGAND; DIABETES MELLITUS, TYPE 2; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; P-SELECTIN;

EID: 77950658721     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.02957.x     Document Type: Article

References (26)

1. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003 26 : 2181 2188.
2. Yngen M, Ostenson CG, Hu H, Li N, Hjemdahl P, Wallén NH. Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004 47 : 537 540.
3. Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003 41 : 1071 1077.
4. Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004 2 : 1282 1291.
5. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007 262 : 157 172.
6. Mason PJ, Chakrabarti S, Albers AA, Rex S, Vitseva O, Varghese S et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 2005 96 : 1365 1369.
7. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003 348 : 1104 1111.
8. Schonbeck U, Varo N, Libby P. Soluble CD40L and cardiovascular risk in women. Circulation 2001 104 : 2266 2268.
9. Zhou L, Stordeur P, de Lavareille A, Thielemans K, Capel P, Goldman M et al. CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost 1998 79 : 1025 1028.
10. Déchanet J, Grosset C, Taupin JL, Merville P, Banchereau J, Ripoche J et al. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol 1997 159 : 5640 5647.
11. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001 89 : 1092 1103.
12. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998 391 : 591 594.
13. Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporarily limited by coexpressed CD40. Blood 2001 98 : 1047 1054.
14. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type-2 diabetes and coronary artery disease. Circulation 2003 107 : 1954 1957.
15. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003 107 : 2664 2669.
16. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001 103 : 491 495.
17. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 348 : 383 393. (Pubitemid 36159355)
18. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004 109 : 2524 2528.
19. Yngen M, Norhammar A, Hjemdahl P, Wallén NH. Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diab Vasc Dis Res 2006 3 : 52 56.
20. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 1994 72 : 979 984.
21. Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complications 2009 23 : 89 94.
22. Michelson AD. Evaluation of platelet function by flow cytometry. Pathophysiol Haemost Thromb 2006 35 : 67 82.
23. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007 14 : 55 61.
24. Cipollone F, Chiarelli F, Davì G, Ferri C, Desideri G, Fazia M et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005 48 : 1216 1224.
25. Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest 2004 34 : 205 209.
26. Keaney JF Jr., Lipinska I, Larson MG, Dupuis J, Freedman JE, Hamburg NM et al. Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study. Am Heart J 2008 156 : 1003 1009.